Research Activity
AstraZeneca’s Truqap Achieves Phase III Success in Prostate Cancer, Reviving Hopes After Breast Cancer Setback
AstraZeneca, Truqap, prostate cancer, Phase III trial, PTEN-deficient metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT).
Axsome Therapeutics Narcolepsy Drug AXS-12 Achieves Phase III Success, Paving Way for US FDA Filing
Axsome Therapeutics, AXS-12, narcolepsy, Phase III trial, ENCORE trial, FDA filing, NDA
Trump’s NIH Leadership Plans: From Jay Bhattacharya to a More Traditional Pick?
Trump, NIH, Jay Bhattacharya, Warp Speed, Leadership, Biomedical Research
Cassava Sciences’ Alzheimer’s Drug Fails in Clinical Trial, Stock Plummets
Cassava Sciences, Alzheimer’s disease, clinical trial failure, ReThink-ALZ study, stock decline
Adcendo Secures $135M for ADC Pipeline Development
Adcendo, ADC pipeline, funding, biotech, cancer treatment, clinical trials
Neurogene’s Rett Syndrome Trial Halted After Patient Death Linked to High-Dose Gene Therapy
Neurogene, Rett syndrome, gene therapy, AAV, clinical trial, patient death, high-dose complications
AstraZeneca Halts Development of Opioid Use Disorder Drug Due to Antifungal Interaction
AstraZeneca, Opioid Use Disorder, Drug Development, Antifungal Interaction, Clinical Trials
Pyxis Oncology Faces Setback as Early ADC Readout in Solid Tumors Fails to Impress
Pyxis Oncology, ADC, PYX-201, solid tumors, clinical trial, stock performance
Amgen Appoints Howard Chang as Senior Vice President of Research and Chief Scientific Officer
Howard Chang, Amgen, Chief Scientific Officer, Research, Biotechnology, Pharmaceutical Industry
The Fallout of Research Misconduct: Implications for Neurodegenerative Disease Studies
Research misconduct, Neurodegenerative diseases, Eliezer Masliah, NIH investigations, Future of neurodegenerative research